MX2022004522A - Formulaciones de liberacion controlada de sustancias fisiologicamente activas altamente lipofilicas. - Google Patents

Formulaciones de liberacion controlada de sustancias fisiologicamente activas altamente lipofilicas.

Info

Publication number
MX2022004522A
MX2022004522A MX2022004522A MX2022004522A MX2022004522A MX 2022004522 A MX2022004522 A MX 2022004522A MX 2022004522 A MX2022004522 A MX 2022004522A MX 2022004522 A MX2022004522 A MX 2022004522A MX 2022004522 A MX2022004522 A MX 2022004522A
Authority
MX
Mexico
Prior art keywords
physiologically active
active substances
highly lipophilic
controlled release
release formulations
Prior art date
Application number
MX2022004522A
Other languages
English (en)
Spanish (es)
Inventor
Annette Grave
Mirko Nowak
Jay Jesko Nowak
Monika Wentzlaff
Sarah Barthold
Christian Geugelin
Original Assignee
Add Advanced Drug Delivery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Add Advanced Drug Delivery Tech Ltd filed Critical Add Advanced Drug Delivery Tech Ltd
Publication of MX2022004522A publication Critical patent/MX2022004522A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022004522A 2019-10-16 2020-10-16 Formulaciones de liberacion controlada de sustancias fisiologicamente activas altamente lipofilicas. MX2022004522A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19203549.1A EP3808336A1 (de) 2019-10-16 2019-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen
PCT/EP2020/079244 WO2021074399A1 (de) 2019-10-16 2020-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Publications (1)

Publication Number Publication Date
MX2022004522A true MX2022004522A (es) 2022-09-19

Family

ID=68281165

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004522A MX2022004522A (es) 2019-10-16 2020-10-16 Formulaciones de liberacion controlada de sustancias fisiologicamente activas altamente lipofilicas.

Country Status (10)

Country Link
US (1) US20240148758A1 (enExample)
EP (2) EP3808336A1 (enExample)
JP (2) JP7850068B2 (enExample)
CN (1) CN114929197A (enExample)
AU (1) AU2020366134B2 (enExample)
BR (1) BR112022006678A2 (enExample)
CA (1) CA3157693A1 (enExample)
IL (1) IL292019A (enExample)
MX (1) MX2022004522A (enExample)
WO (1) WO2021074399A1 (enExample)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
SK287111B6 (sk) * 1998-08-27 2009-12-07 Pharmacia & Upjohn Ab Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
WO2012048045A1 (en) * 2010-10-05 2012-04-12 Jb Therapeutics, Inc. Compositions, dosages, and methods of using tetrahydrocannabinol derivatives
US9943491B2 (en) 2013-10-29 2018-04-17 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
US20190201350A1 (en) 2016-08-15 2019-07-04 Corr-Jensen Inc. Time release of fat-soluble actives
EP3808341A1 (de) * 2019-10-16 2021-04-21 ADD Advanced Drug Delivery Technologies, Ltd. Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Also Published As

Publication number Publication date
AU2020366134B2 (en) 2026-04-23
US20240148758A1 (en) 2024-05-09
EP3808336A1 (de) 2021-04-21
CN114929197A (zh) 2022-08-19
WO2021074399A1 (de) 2021-04-22
JP2026034780A (ja) 2026-02-27
CA3157693A1 (en) 2021-04-22
JP7850068B2 (ja) 2026-04-22
BR112022006678A2 (pt) 2022-07-12
JP2022553652A (ja) 2022-12-26
AU2020366134A1 (en) 2022-05-26
IL292019A (en) 2022-06-01
EP4045007A1 (de) 2022-08-24

Similar Documents

Publication Publication Date Title
UY38602A (es) Compuestos tricíclicos condensados
BR112022024943A2 (pt) Composição oral efervescente compreendendo um ingrediente ativo
DOP2022000053A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
WO2020016659A3 (en) Multiparticulate formulations of cannabinoids
UY38403A (es) Moduladores de la alfa-1 antitripsina
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
ECSP18082774A (es) Derivados aromáticos de sulfonamida
PE20201163A1 (es) Composiciones y tratamientos para el trastorno del sueno
CL2020002252A1 (es) Formulación oftálmica.
AR086409A1 (es) Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino
CL2018001510A1 (es) Composición farmacéutica que comprende un potente inhibidor de urat1
CL2018000712A1 (es) Adyuvantes mejorados para productos agroquímicos
MX2022004523A (es) Formulaciones de liberacion controlada para sustancias fisiologicamente activas altamente lipofilicas.
CL2020002101A1 (es) Formulaciones de liberación sostenida de ácido bempedoico.
MX2022006903A (es) Productos orales con irritacion reducida.
MX2021012904A (es) Moduladores de la via de respuesta al estres integrada.
PY1929301A (es) Formulación sólida de mezclas insecticidas.-
AR054234A1 (es) Composicion farmaceutica para el tratamiento del cancer
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
MX390536B (es) Composicion farmaceutica topica que comprende al menos amitriptilina para el tratamiento del dolor neuropatico periferico.
CO2020005366A2 (es) Composición plaguicida que contiene tidiazurón y ácido poliglutámico
MX2023011701A (es) Composicion farmaceutica para liberacion controlada de treprostinil.
EP3760195A4 (en) COMPOSITION WITH 2,3-BUTANEDIOL AS THE ACTIVE SUBSTANCE
CO2022008308A2 (es) Tieniloxazolonas y análogos